Xcenda Publications Archive

These citations highlight the scientific publications authored by our associates.

2009

Fernandez-Lopez S, Lennert B. Quality Improvement Initiatives: The Miss Opportunity for Health Plans. Am Health & Drugs Benefits. 2009 Nov/Dec; 2(7):297-304.

Saverno K, Seal B, Goodman MJ, Meyer K. Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis. American Health & Drug Benefits. 2009 Nov/Dec; 2(7):309-316.

Lennert B. Care Management for TIA and Stroke Patients: Riding the Quality Improvement Wave. Am Health & Drugs Benefits. 2009 Sept/Oct;2(8):S24-S27

Min JK, Gilmore A, O’Day K, Budoff MJ. The Cost-effectiveness of coronary computed tomography Angiography versus Myocardial perfusion SPECT imaging for the evaluation of patients with chest pain and no known coronary artery disease. Radiology. In Press.

Green MR, West H, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, Lovino, L. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with Stage IIIB non-small cell lung cancer. J Thoracic Oncol. 2009;4(8):983-987.

Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries Haemophilia. 2009;15(5):1083-1089.

Garris C, Shah M, D’Souza A, Stanford R. Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms: retrospective cohort analysis of pharmacy claims data. Clin Drug Invest. 2009;29(8):515-526.

Feinberg B, Gilmore J, Gondesen T, Jackson J, Saleh M. Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Community Oncol. 2009;6(6):257-261.

Meissner B, Nelson W, Hicks R, Sikirica V, Gagne J, Schein J. The rate and costs attributable to intravenous patient-controlled analgesia errors. Hosp Pharm. 2009;44(4):312-314.

Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek O, Happe L. Economic and clinical evaluation of foundaparinux vs enoxaparin for thromboprophylaxis following general surgery. CMRO. 2009;25(5):1081-1087.

Happe L, Lunacsek O, Kruzikas D, Marshall G. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J. 2009;28(2):98-101.

O’Day K, Salamanca-Brosig L, Regan T, Boswell K, Seal B, Reeder G. Asthma disease burden and formulary decision making: MCO and employer perspectives. Drug Benefit Trends. 2009;21(2):43-49.

Reeder C, Divers C, Deem D, Cherney B, Fortner G, Probst L. Employer-based health initiative: impact on employees’ cardiovascular outcomes. Am Health Drug Benefits. 2009;2(2):80-85.

Jackson J, Gutierrez B, Lunacsek O, Ramachandran S. Better asthma management with advanced technology: creation of an asthma utilization Rx analyzer (AURA) tool. P&T. 2009;34(2):80-85.

Wall B, Chiao E, Plauschinat C, Miner P, Jackson J, Humphrey B. Trends from the field: provider organization performance assessment utilizing diabetes physician recognition program Am J Manag Care. Feb 2009 – ajmc.com.

Sarnes M. Impact of market trends on drug pipelines: the need for value-based R&D. Am Health Drug Benefits. 2009;2(1 Suppl):S55-S60.

2008

Hines JL., Danciu SC., Shah M, Borg MJ, Biga C. Use of multidetector computed tomography after mildly abnormal myocardial perfusion stress testing in a large single-specialty cardiology practice , Journal of Cardiovascular Computed Tomography 10 Oct 2008: 2(6):372-378.

Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. “Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma.” Arch Ophthalmol. 2008 Jun;126(6):849-56

Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits. 2008;1(8):26-34.

Jackson J, Sobolski J, Krienke R, Wong K, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7 Guidelines). J Am Board Fam Med. 2008;2(1):512-521.

Sheehan D, Keene M, Eaddy M, Krulewicz S, Kraus JE, Carpenter D. Differences in medication adherence and healthcare resource utilization patterns; older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22(11):963-973.

Comp P, Happe LE, Sarnes MW, Farrelly E. Clinically detected venous thromboembolism following hip fracture surgery with prophylaxis in a clinical practice setting. Am J Orthop. 2008;37(9):470-475.

Eaddy M, Shah M, Lunacsek O, Stanford R. The burden of illness of hypertension and comorbid diabetes. Curr Med Res Opin. 2008;24(9):2501-2507.

Stanford E, Chen A, Wan G, Lunacsek O, Sand P. Treatment modalities, health care resource utilization, and costs in patients diagnosed with interstitial cystitis. Am J Obstet Gynecol. 2008;199(1):71.e1-10.

Kwong LM, Happe LE, Horblyuk R, Farrelly E. Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery. J Arthroplasty. 2008;23(6 Suppl 1):25-30.

Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, Franklin M. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery. Ann Pharmacother. 2008;42(9):1216-1221.

Shorr AF, Nutescu EA, Farrelly E, Horblyuk R, Happe LE, Franklin M. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. Ann Pharmacother. 2008;42(9):1222-1228.

Naslund M, Eaddy M, Kruep E, Hogue S. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. Am J Manag Care. 2008;14(5):S167-S172.

Issa M, Lin P, Eaddy M, Shah M, Davis EA. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. Am J Manag Care. 2008;14(5):S160-S166.

Fenter T, Davis EA, Shah M, Lin P. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged 65 years. Am J Manag Care. 2008;14(5):S154-S159.

Naslund M, Regan T, Ong C, Hogue S. 5-alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. Am J Manag Care. 2008;14(5):S148-S153.

Shabsigh R, Shah M, Sand M. Erectile dysfunction and men’s health: developing a comorbidity risk calculator. J Sex Med. 2008;5:1237-1243.

D’Souza A, Smith M, Miller L, Doyle J, Ariely R. Persistence, adherence and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291-301.

Reeder C, Franklin M, Bramley T. Managed care and the impact of glaucoma. Am J Manag Care. 2008;14:S5-S10.

Levin L, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care. 2008;14:S11-S14.

Varma R, Peeples P, Walt J, Bramley T. Disease progression and the need for neuroprotection in glaucoma management. Am J Manag Care. 2008;14:S15-S19.

McKinnon S, Goldberg L, Peeples P, Walt J, Bramley T. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14:S20-S27.

Fang E, Law S, Walt J, Chiang T, Williams E. The prevalence of glaucomatous risk factors in patients from a managed care setting: a pilot evaluation. Am J Manag Care. 2008;14:S28-S36.

Hicks RW, Sikirica V, Nelson W, Schein JR, Cousins DD. Medication errors involving patient-controlled analgesia. Am J Health-Syst Pharm. 2008;65(5):429-440.

2007

Bramley T, Franklin M, Mitrzyk B, et al. Management and treatment of insomnia and its impact on today’s managed care. Am J Manag Care. 2007;13(5):S110-S111.

Reeder C, Franklin M, Bramley T. Current landscape of insomnia in managed care. Am J Manag Care. 2007;13(5):S112-S116.

Roth T, Franklin M, Bramley T. The state of insomnia and emerging trends. Am J Manag Care. 2007;13(5):S117-S120.

Navarro R, Mitrzyk B, Bramley T. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations. Am J Manag Care. 2007;13(5):S121-S124.

Richardson G, Mitrzyk B, Bramley T. Circadian rhythmicity and the pharmacologic management of insomnia. Am J Manag Care. 2007;13(5):S125-S128.

Green, M R., Dowlati, A., Yellamraju, L., Daniels, L., Willey, J., Andrews, M., Leff, R.,

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000-2006. Journal of Thoracic Oncology October 2007; 2(10): 953-956.

Happe L, Lunacsek O, Marshall G, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506-512.

Marshall G, Happe L, Lunacsek O, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496-500.

Black L, Runken MC, Eaddy M, Shah M. “Chronic disease prevalence and burden in elderly men: an analysis of Medicare medical claims data.” Journal of Health Care Finance. 2007 Summer;33(4):68-78.

Shabsigh R, Duval S, Shah M, Regan T, Juhasz M, Veltry L. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: meta-analysis of clinical trial data. Curr Med Res Opin. 2007;23(10):2453-2460.

Hymes J, Bickimer T, Jackson J, Bookhart B, Mody S, Piech C. Dosing patterns, drug costs and hematologic outcomes in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Curr Med Res Opin. 2007;23(8):1931-1937.

Vargo JJ, Bramley T, Meyer K, Nightengale B. Practice efficiency and economics: the case for rapid recovery sedation agents for colonoscopy in a screening population. J Clin Gastroenterol. 2007;41(6):591-598.

Evans C, Schein J, Nelson W, et al. Improving patient and nurse outcomes: a task and time associated with two patient-controlled analgesia modalities using Delphi panels. Pain Manag Nurs. 2007;8(2):86-95.

St Louis EK, Gidal BE, Henry TR, et al. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav. 2007;11(2):222-234.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb Res. 2007;121(1):17-24.

Posten S, Dickson M, Johnsrud M, et al. Topiramate prescribing patterns among Medicaid patients: diagnosis, comorbidities, and dosing. Clin Ther. 2007;(3):504-518.

Harding G, Vallow S, Leidy N, et al. Ease of care with patient controlled analgesia system: questionnaire development and validation. J Adv Nurs. 2007;59(5):530-541.

Issa M, Regan T. Medical therapy for benign prostatic hyperplasia – present and future impact. Am J Manag Care. 2007;13(1 Suppl):S4-S9.

Issa M, Runken C, Grogg A, Shah M. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care. 2007;13(1 Suppl):S10-S16.

Naslund M, Black L, Eaddy M, Batiste L. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5ARIs. Am J Manag Care. 2007;13(1 Suppl):S17-S22.

Fenter T, Runken C, Black L, Eaddy M. Finasteride versus dutasteride: a real-world economic evaluation. Am J Manag Care. 2007;13(1 Suppl):S23-S27.

Goldstein J, Matuszweski K, Delaney C, Senagore A, Chiao E, Shah M, Meyer K, Bramley T. Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. P&T. 2007;32(1,2)[LK1] .

Raebel MA, McClure DL, Chan KA, et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother. 2007;41:193-200.

Shah M, Butler M, Bramley T, Curtice T, Fine S. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Curr Med Res Opin. 2007;23(2):417-426.

Rolnick SJ, Jackson J, Nelson WW, et al. Pain management in the last six months of life among women who died of ovarian cancer. J Pain Symptom Manage. 2007;33: 24-31.

Happe L, Farrelly E, Stanford R, Sarnes M. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. J Thromb Thrombolysis. Published online 11/2007; 26: 125-131.

2006

Jackson J, Fernandes A, Nelson W. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: a retrospective data analysis. Clin Ther. 2006;28(9):1462-1471.

Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-245.

Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating adherence of antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300-303.

Gdovin JM, Moya F, Vishalpura T, Grogg A. A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome. J Pediatr Pharmacol Ther. 2006;11(1):43-54.

Naslund MJ, Chiao E, Black L, Eaddy MT. The hidden condition: status, challenges, and opportunities in the management of enlarged prostate for managed care. Am J Manag Care. 2006;12(4 Suppl):S76-S82.

Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 Suppl):S83-S89.

Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 Suppl):S90-S98.

Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care. 2006;12(4 Suppl):S111-S116.  

Meissner B, Dickson M, Shinogle J. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12(4):331-340.

Raebel MA, McClure DL, Simon SR, et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother. 2006;40:386-391.

Solberg LI, Enstad CJ, Boyle RG, Nelson WW. Physician-patient interaction for smoking cessation medications: a dance of mutual accommodation? J Am Board Fam Med. 2006;19:251-257.

Patric K, Stickles J, Turpin R, et al. Diabetes disease management in Medicaid managed care: a program evaluation. Dis Manag. 2006;9(3):144-156.

Stein M, Cantrell R, Sokol M, et al. The national anxiety managed care database: a focus on antidepressant utilization, patient adherence, and resource utilization. Psychiatr Serv. 2006;57(5):673-680.

Goodman MJ, Nordin J. Vaccine adverse event reporting system reporting source: a possible source of bias in longitudinal studies. Pediatrics. 2006;117(2)387-390.

Goodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics. 2006;117(5):e821-826.

Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31(1):52-61.

Maciosek MV, Edwards NM, Coffield AB, et al. Priorities among effective clinical preventive services: methods. Am J Prev Med. 2006;31(1):90-96.

Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med. 2006;31(1):80-89.

Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006;31(1):72-79.

Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med. 2006;31(1):62-71.

Raebel MA, Carroll NM, Simon SR, et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm. 2006;12:656-664.

Raebel MA, Carroll NM, Andrade SE, et al. Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care. 2006;12:268-274.

Meissner B, Harrison D, Carter J, Borrego M. Predicting the impact of Medicare Part D implementation on the pharmacy workforce. Res Social Adm Pharm. 2006; 2(3):315-328.

Dornbusch D., Allegra C., Willey J., Andrews M., Leff R., Epstein J., Jones J., Lokey L., Green M R., How Do U.S. Medical Oncologists Learn and Apply New Clinical Trials Information from Press Releases in Nonmedical Media? A Case Study Based on ECOG 4599 The Oncologist January 2006; 11(1): 31-38.

2005

DeVane CL, Chiao E, Franklin M, Kruep E. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. Am J Manag Care. 2005;11(Suppl):S344-S353.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care. 2005;11(Suppl):S354-S361.

Keene M, Eaddy M, Nelson WW, Sarnes MW. Adherence to proxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care. 2005;11(Suppl):S362-S369.

Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care. 2005;11(Suppl):S370-S379.

Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther. 2005;27(2):263-272.

Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE. Relationship of total health care charges to SSRI utilization patterns including the length of antidepressant therapy. J Manag Care Pharm. 2005;11(2):145-150.

Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes MW. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis. Manag Care Interface. 2005;18(1):55-63.

Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care. 2005;11(4):206-210.

Green M., Andrews M., Leff R., Willey J., Allegra C., Denes A., Epstein J., Jones J., Lokey L., Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data. Journal of Oncology Practice, 2005; 1(2): 37-42.

Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data. Journal of Oncology Practice,; 1(2): 37-42.

Hurley JS, Roberts M, Solberg LI, et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med. 2005;20(4):331-333.

Johnsrud M, Crismon Ml, Thompson A, Grogg A. An economic comparison of risperidone and olanzapine use within an integrated managed mental health program. Adm Policy Men Health. 2005;20:1-7.

Kaliner M, Amin A, Gehling R, et al. Impact of inhaled corticosteroid-induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi panel. Pharm Ther Dig. 2005;30(10):573-601.

Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165:2497-2503.

Keene MS, Eaddy MT, Mauch RP, Regan TS, Shah M, Chiao E. Differences in compliance patterns across the SSRIs. Curr Med Res Opin. 2005;21:1651-1658.

Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm. 2005;62(24):2597-2603.

Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43(10):951-959.

Sheehan D, Chiao E, Eaddy M, Shah M, Sarnes M. Differences in patterns of therapy change across the SSRIs for treatment of depression and anxiety. Drug Benefit Trends. 2005;17:403-410.

Simon SR, Andrade SE, Ellis JL, et al. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. J Am Geriatr Soc. 2005;53(12):2165-2169.

Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol. 2005;58(2):171-174.

Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-341.

Goodman MJ, Nelson WW, Maciosek MV. Births by day of week: a historical perspective. J Midwifery Womens Health. 2005;50(1):39-43.

2004

Jackson J, Frech F, Ronen R, Mullany L, Lennert B, Jhaveri V. Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension. J Manag Care Pharm. 2004;10(6):513-520.

Kennedy DT, Paulson DM, Eddy TD, et al. A smoking-cessation program consisting of extensive counseling, pharmacotherapy, and office spirometry: results of a pilot project in a Veterans Administration medical center. Pharmacotherapy. 2004;24(10):1400-1407.

Nelson WW, Sybilrud LE, Porter DR, et al. Erroneous manufacturer-assigned thromboplastin reagent ISI value. Lab Med. 2004;35(6):327-328.

Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. Am J Manag Care. 2004;10(6):383-391.

McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. Clin Ther. 2004;26(1):115-124.

Mladsi DM, Grogg AL, Irish WD, et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004;20(12):1883-1893.

Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Non-sedating antihistamine utilization impact following an increase in prescription co-payment. J Manag Care Pharm. 2004;10(3):226-233.

Sarnes MW, Frankum (Happe) LE. Pharmacoeconomic evaluation of antidepressant therapies. Manag Care. 2004;13(Suppl 6):34-41.

Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation. J Clin Psychopharmacol. 2004;24:544-548.

Solberg LI, Hurley JS, Roberts MH, et al. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care. 2004;10(11 Pt 1):753-759.

Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov Model. Value Health. 2004;7(5):569-584.

Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.

Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590.

Saver BG, Ritzwoller DP, Maciosek M, et al. Does payment drive procedures? Payment for specialty services and procedure rate variations in 3 HMOs. Am J Manag Care. 2004;10(3):229-237.

2003

Sapienza S, Sacco P, Floyd (Flemister) K, DiCesare J, Doan QD. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003;25(6):1872-1887.

Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuance: a comparison of controlled-release paroxetine and immediate-release SSRIs. Manag Care Interface. 2003;16(12):22-27.

Fendrick AM, Monto AS, Sarnes MW, Nightengale BS. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487-494.

Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23(8):1037-1043.

Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther. 2003;25(4):1150-1171.

Godley P, Nguyen A, Yokoyama K, Rohack J, Woodward B, Chiang T. Improving hypertension care in a large group-model MCO. Am J Health Syst Pharm. 2003;60(6):554-564.

Holdford D, Patkar A. Identification of the service quality dimensions of pharmaceutical education. Am J Pharm Educ. 2003;67(4):article 108.

Maue SK, Jackson JH, Weiss BA, et al. The hypertension management program: identifying opportunities for improvement. J Clin Hypertens. 2003;3(Suppl 2):33-40.

Monto AS, Bramley TJ, Sarnes M. Development of a predictive index for picornavirus infections. Clin Infect Dis. 2003;36:253-258.

Offman JJ, Segal R, Russell WL, et al. A randomized trial of an acid-peptic disease management program in a managed care environment. Am J Manag Care. 2003;9(6):425-433.

Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163(17):2052-2057.

Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the Rx risk model. Med Care. 2003;41(1):84-99.

2002

Bramley TJ, Lerner D, Sarnes M. Productivity losses related to the common cold. J Occup Environ Med. 2002;44:822-829.

Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Nasrallah H. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.

Girts TK, Crawford AG, Goldfarb NI, Bachleda M, Grogg A. Predicting high utilization of emergency department services among patients with a diagnosis of psychosis in a Medicaid managed care organization. Dis Manag. 2002;5(4):189-196.

Jackson JH, Bramley TJ, Chiang TS, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in an African-American hypertensive population. Ethn Dis. 2002;12(4 Suppl 3):53-57.

Maue SK, Rivo ML, Weiss B, et al. Effect of a primary care physician-focused, population-based approach to blood pressure control. Fam Med. 2002;34(7):508-513.

Offman J, Shaw M, Sadik K, et al. Identifying patients with gastroesophageal reflux disease — validation of a practical screening tool. Dig Dis Sci. 2002;47(8):1863-1869.

Mahmoud R, Kozma C, Reeder CE, Grogg AL, Meissner B. The role of pharmaceuticals in mental health care outcomes. In: Neuropsychopharmacology – 5th Generation of Progress. Nashville, TN: American College of Neuropsychopharmacology; 2002.

Andrade SE, Gurwitz JH, Chan KA, et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol. 2002;55(3):310-313.

Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med. 2002;162(8):936-942.

Fischer LR, Defor TA, Cooper S, et al. Pharmaceutical care and health care utilization in an HMO. Eff Clin Pract. 2002;5(2):49-57.

Putnam KG, Buist DS, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology. 2002;13(3):340-346.

2001

Godley P, Pham H, Woodward B, Rohack J, Maue SK. Opportunities for quality improvement in hypertension care in a managed care setting. Am J Health Syst Pharm. 2001;58(18):1728-1733.

Mauch R, Goldstein W, Lutes M, et al. Pharmaceutical industry and payer partnerships: program overview, legal updates and panel discussion proceedings. Manag Care. 2001;10(9 Suppl):5-6.

Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: a review of clinical outcomes. Clin Ther. 2001;23(10):1615-1627.

Ofman J, Ryu S, Borenstein J, et al. Identifying patients with gastroesophageal reflux disease in a managed care organization. Am J Health Syst Pharm. 2001;58(17):1607-1613.

Phillips C, Polakoff D, Mauch RP, Maue SK. Assessment of constipation management in long-term care patients. J Am Med Dir Assoc. 2001;2(4):149-154.

Platt R, Davis R, Finkelstein J, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for education and research on therapeutics. Pharmacoepidemiol Drug Saf. 2001;10(5):373-377.

2000

Floyd (Flemister) KM, Maue SK, Aqui W, Augello F. The prevalence and treatment patterns of constipation in the long-term care setting: a multicenter cross-sectional study. Consultant Pharmacist. 2000.

Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease patients converted from omeprazole to lansoprazole. Arch Intern Med. 2000;160(16):2491-2496.

Polakoff D, Tuell KT, Collette A, Wolfe M, Floyd (Flemister) KM. Collaborative partnership for optimizing heart failure outcomes in the long-term care environment: a disease management experience. J Am Med Dir Assoc. 2000;1(5):217-222.

MaueSK, Segal R. Application of pharmacoeconomics and decision analysis in gastrointestinal disorders in the context of disease management. Introduction to Applied Pharmacoeconomics. Chapter 8:144-178.

Sarnes MW, Doan Q. Impact of drug interactions and adverse reactions on therapeutics. In: Pharmacotherapeutics for Advanced Practice, 1st edition. Arcangelo V, Peterson A, eds. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.

Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme a reductase and risk of fracture among older women. Lancet. 2000;355(9222):2185-2188.

Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA. 2000;284(23):3036-3039.

1996–1999

Lee J, Lawrence BJ, Sullivan SD, et al. Guidelines for pharmacoeconomic research fellowships. Pharmacotherapy. 1999;19(9):1105-1109.

Nelson WW, Frear RS. Physician attitudes toward human growth hormone products. Am J Health Syst Pharm. 1999;56(1):51-56.

Willey VJ, Sarnes MW, Cziraky MJ. Counseling the patient with hyperlipidemia. Pharm Times. June 1999.

Gourley DR, Gourley GA, Solomon DK, et al. Part 1: development, implementation and evaluation of a multicenter pharmaceutical care outcomes study. J Am Pharm Assoc. 1998;38(5):567-573.

Solomon DK, Portner TS, Bass GE, et al. Part 2: clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc. 1998;38(5):574-585.

Maine LL, Regan TS. Integrated pharmacy services: cornerstone of a new model of care at Celebration Health. J Am Pharm Assoc. 1998;38(2):131-136.

Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents versus risperidone. Psychopharmacol Bull. 1998;34:373-382.

Nightengale BS, Garrett MS, Waugh S, Lawrence BJ, Andrus J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am J Manag Care. 1998;4:400-407.

Nightengale BS, Mauch RP. Granisetron in the treatment of chemotherapy-induced nausea and vomiting: a pharmacoeconomic review. P&T. 1998;23:119-132.

Donahue JG, Andrade SE, Cain EM, et al. Lamotrigine and severe skin eruptions. Pharmacoepidemiol Drug Saf. 1998;7(6):415-417.

Kernodle (Maue) SJ. Improving health care with clinical practice guidelines and critical pathways:  implications for pharmacists in ambulatory practice. Pharm Pract Manag Q. 1997;17(3):76-89.

Lim D, Farup C, Lawrence BJ, et al. Gastrointestinal illness in managed care: healthcare utilization and costs. Am J Manag Care. 1997;3(12):1859-1872.

Splinter MY, Sagraves R, Nightengale BS, Rayburn WF. Prenatal use of medications by women giving birth at a university hospital. South Med J. 1997;90(5):498-502.

Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of health-care resources. Psychiatr Serv. 1997;48(9):1153-1159.

Abbott TA, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines.  Clin Ther. 1996;18(1):127-149.

Mauch RP, Lawrence BJ, Nissenbaum R, Dallman J. Clinical and economic impact of fluvastatin on a managed care formulary. Manag Care Med. 1996;3(3):28-35.

Nightengale BS, Savage G. Oxygen transport, delivery and tuberculosis protection in the perianesthesia care unit (PACU): a cost study. J Perianesth Nurs. 1996;11:1-8.

Payne K, Kozma CM, Lawrence BJ. Comparing DHE and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. Pharmacoeconomics. 1996;10(1):59-71.

Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists' perceptions of a common interaction classification scheme. Ann Pharmacother. 1996;30:926-934.

1991–1995

Kozma CM, Motheral B, Lawrence BJ. Outcomes research and pharmacoeconomics for practicing pharmacists. Sandoz Continuing Education Series. 1995;8(1):1-15.

Nightengale BS. Cost-effectiveness of Tl-201 and Tc-99m sestamibi. J Nucl Med Technol. 1995;23:36-41.

Nightengale BS, Brune MB, Blizzard SP, et al. Strontium-89 chloride for the palliative treatment of metastatic bone disease. Am J Health Syst Pharm. 1995;52:2189-2195.

O'chi H, Kuwayama T, Tanaka N, Hess GP, Kozma CM, Grogg AL. Japanese pharmacoeconomic survey. Institute for Health Economics and Policy, Tokyo, Japan. 1995.

Hornbrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 Health Survey. Inquiry. 1995; 32(1):56-74.

Grogg AL, Pittman D. Beta-blockers in congestive heart failure (CE article). Georgia J Hospital Pharm. 1994;8(1):8-12.

Kozma CM, Mauch RP, Reeder CE, Lawrence BJ. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clin Ther. 1994;16(6):137-152.

Pakulski L, Grogg AL. Steroid pretreatment for ionic contrast media. P&T. 1994;19(6):648.

Reeder CE, Lingle EW, Schulz RM, et al. Economic impact of cost-containment strategies in third party programmes in the US (part I). Pharmacoeconomics. 1993;(2):92-103.

Hawkins D, Jackson J. Application of pharmacoeconomics in cardiovascular disease: economic evaluation of lipid-lowering therapies. Introduction to Applied Pharmacoeconomics. Chapter 9:179-196.